

AD _____

Award Number: DAMD17-03-1-0447

TITLE: A Population-Based Randomized Trial to Assess the Effects of Short-Term Cessation of HRT on Mammography Assessments and Breast Density

PRINCIPAL INVESTIGATOR: Diana S. Buist, Ph.D.
Katherine Newton, Ph.D.
Susan Reed, M.D.
Elizabeth King

CONTRACTING ORGANIZATION: Group Health Cooperative of Puget Sound
Seattle, Washington 98101-1448

REPORT DATE: June 2004

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20041215 013

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE June 2004	3. REPORT TYPE AND DATES COVERED Annual (1 Jun 03-31 May 04)	
4. TITLE AND SUBTITLE A Population-Based Randomized Trial to Assess the Effects of Short-Term Cessation of HRT on Mammography Assessments and Breast Density			5. FUNDING NUMBERS DAMD17-03-1-0447	
6. AUTHOR(S) Diana S. Buist, Ph.D. Katherine Newton, Ph.D. Susan Reed, M.D. Elizabeth King				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Group Health Cooperative of Puget Sound Seattle, Washington 98101-1448 E-Mail: buist.d@ghc.org			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) This randomized controlled trial is designed to test whether short-term (1-2 months) HRT cessation will sufficiently lower breast density to decrease the proportion of women who receive a recommendation for additional evaluation following a screening mammogram, and to examine whether there is a trend by duration of cessation. The study will be conducted at Group Health Cooperative, a managed health care organization with an organized breast cancer screening program. A total of 1500 women will be recruited and randomized to one of three HRT arms: 1) cessation two months before the screening mammogram, 2) cessation one month before, and 3) continued HRT use. Breast density will be measured using a computer assisted method and recall rates will be determined from an expert radiologist review of the mammograms, blinded to HRT status. The study team has developed operational procedures and all study materials, including questionnaires and other data collection forms, recruitment and informational materials, consent form, DSMB reports. These materials have received full approval from the local IRB and have been approved with stipulations by the HSRRB. We are revising the protocol and materials in response to the HSRRB. A tracking system has also been developed.				
14. SUBJECT TERMS Randomized controlled trial, mammography, health care setting, hormone replacement therapy, breast density				15. NUMBER OF PAGES 7
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

Table of Contents

Cover Page	1
Standard form 298	2
Table of Contents	3
Introduction	4
Body	4
Key Research Accomplishments	5
Reportable Outcomes	6
Conclusions	6
References	6
Appendix:	
List Of Study Materials Developed and Submitted for HSRRB Review	7

INTRODUCTION:

This randomized controlled trial is designed to test whether short-term (1-2 months) HRT cessation will sufficiently lower breast density to decrease the proportion of women who receive a recommendation for additional evaluation following a screening mammogram, and to examine whether there is a trend by duration of cessation. The study will be conducted at Group Health Cooperative, a managed health care organization with an organized breast cancer screening program. WE will use automated to identify HRT users who are due for screening mammograms. Women will be recruited through mailed correspondence and telephone contact. A total of 1500 women will be recruited and randomized to one of three HRT arms: 1) cessation two months before the screening mammogram, 2) cessation one month before, and 3) continued HRT use. Breast density will be measured using a computer assisted method and recall rates will be determined from an expert radiologist review of the mammograms, blinded to HRT status. We will test whether: 1) HRT cessation 1 or 2 months before a screening mammogram reduces the likelihood of receiving a recommendation for additional evaluation compared to women who continue using HRT; 2) HRT cessation for 1 versus 2 months affects the likelihood of receiving a recommendation for additional evaluation; and 3) there is a greater change in breast density (to lower breast density) among women who stop HRT 1 or 2 months before a screening mammogram to those who do not stop HRT. Change in breast density will be measured as the difference between breast density on the screening mammogram before the trial (while on HRT) and during the trial. As part of this trial we will also evaluate: 1) women's tolerance (defined as continued cessation) for short-term (1-2 months) HRT cessation, 2) the rate of HRT re-initiation after participation in the trial, 3) rates of reported adverse events (return of hot flashes, thromboembolic events within the first 6-months after re-initiation, and return of bleeding with re-initiation among previously amenorrheic women) across randomization groups.

BODY:

Over the past year, members of the study team have developed the protocol, detailed operational procedures and all study materials, including: questionnaires and other data collection forms; informational materials for health care providers; recruitment and participant information materials; consent form; and Data Safety and Monitoring Board (DSMB) reports (see appendix for list of study materials). We worked closely with all study team members including the study nurse and study physician, as well as with members of the lay advisory committee and the DSMB. After an intensive process, the protocol and study materials received full approval from the local IRB in November of 2003.

The IRB-approved materials and other required elements were submitted to the DOD HSRRB on December 4, 2003. The HSRRB provided us with a Memorandum for Record (MFR) on March 16, 2004, which we responded to, making changes to the protocol and study materials as required or recommended. We received a second MFR on May 14, 2004, which we are currently in the process of responding to. The study received a full review by the HSRRB on May 26, 2004. We were notified that we were approved with stipulations, but have not yet received the official minutes from the review with specific items requiring a response or modifications. We have, however, begun revising the protocol and materials based on the MFR received on May 16 and on the feedback received during the review and in subsequent communications with the HSRRB. All revised materials will be

submitted to the HSRRB for final approval and subsequently submitted to the local IRB for approval of all modifications.

A computerized database has been developed to track all operational aspects of study participation. We have been working with key individuals in the delivery/clinical system to ensure that aspects of the study that impact the clinical system will run smoothly and with as little impact on the clinical system and as little inconvenience for the study participant as possible.

Unanticipated delays in starting recruitment:

At this point, we are substantially behind our schedule for starting to recruit women. This has been in large part because of delays in human use approval by the Department of Defense. We submitted our final application to the HSRRB December 4, 2003 and at this point (June 29, 2004) we have not yet received our final minutes from our HSRRB review. However, we have incurred significant costs associated with developing study materials and responding to our local IRB and the HSRRB. Thus, we anticipate that we may have difficulty recruiting 1500 women by the end of the study period (May 31, 2006).

Below we outline our progress on the scope of work outlined in our original proposal.

Task A. Recruit 1500 women to participate in the trial

We have detailed our recruitment plan, developed a tracking database, and written computer programs to link eligible women for recruitment (tasks 1-3). The remaining tasks will be worked once we start recruitment.

Task B. Develop Study Materials

We have developed all study materials including baseline and follow-up questionnaires, instructions on HRT cessation and re-initiation, procedures of operation, and have developed and met with our advocacy board (they have reviewed and provided feedback for all study materials). All items in Task B have been completed.

Task C. Monitor the safety of HRT cessation and initiation

We have formed our DSMB, developed a prototype for our DSMB report, held our first study meeting with the DSMB and have had all study materials reviewed and approved by our DSMB. We will generate our DSMB reports once our study is underway.

Task D. Study staff read all films for clinical interpretation and breast density measurements for the screening mammograms, blinded with respect to HRT status. Validate HRT cessation/use. & **Task E.** Data quality and control & **Task F.** Final analyses and report writing

We have not completed any portion of tasks D, E and F, since all elements from these tasks require women to be recruited into the study.

KEY RESEARCH ACCOMPLISHMENTS:

As of June 24, 2004, we have:

- Developed all recruitment and data collection materials (see Attached List)

- Established and met with and had all study materials reviewed our Data Safety and Monitoring Board
- Established, met with and had all study materials reviewed by our Advocacy Board
- Received local human subjects approval for all study materials
- Received approval with stipulations from the HSRRB

REPORTABLE OUTCOMES:

The research portion of this study has not begun. We expect to begin enrollment for the study in August 2004, provided we are able to receive all necessary human subjects approvals by that time.

CONCLUSIONS:

We do not have any results to report at this time since we have not yet started recruitment.

REFERENCES:

N/A

Appendix: List Of Study Materials Developed and Submitted for HSRRB Review

1. Informational Letter to all Primary Care Physicians
2. Letter to Primary Care Physicians Requesting Approval of Patients
3. Initial Recruitment Letter to Subject
4. Study Brochure
5. Telephone Screening Script
6. Consent Form
7. Thank You Letter
8. Long Term Risks of HRT Use Fact Sheet
9. Consent Form Cover Letter to Subject
10. Follow-Up Letter To Physicians Informing of Patient Participation
11. Cover Letter to Subject: Group 1
12. Cover Letter to Subject: Group 2
13. Cover Letter to Subject: Group 3
14. Baseline Questionnaire
15. Study Instructions Group 1
16. Study Instructions Group 2
17. Study Instructions Group 3
18. Cover Letter to Subject: Follow-Up Questionnaire
19. Follow-up Questionnaire Groups 1&2
20. Follow-up Questionnaire Group 3
21. Adverse Events Report
22. DSMB Open Report
23. DSMB Closed Report
24. Adverse Events Flow Chart
25. HSRRB Application/protocol